CN116669763A - Fgfr抑制剂联合疗法 - Google Patents
Fgfr抑制剂联合疗法 Download PDFInfo
- Publication number
- CN116669763A CN116669763A CN202180076145.8A CN202180076145A CN116669763A CN 116669763 A CN116669763 A CN 116669763A CN 202180076145 A CN202180076145 A CN 202180076145A CN 116669763 A CN116669763 A CN 116669763A
- Authority
- CN
- China
- Prior art keywords
- genetic alteration
- inhibitor
- patient
- fgfr3
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078193P | 2020-09-14 | 2020-09-14 | |
| US63/078193 | 2020-09-14 | ||
| PCT/EP2021/075145 WO2022053697A1 (en) | 2020-09-14 | 2021-09-13 | Fgfr inhibitor combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116669763A true CN116669763A (zh) | 2023-08-29 |
Family
ID=77821784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180076145.8A Pending CN116669763A (zh) | 2020-09-14 | 2021-09-13 | Fgfr抑制剂联合疗法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230321087A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4210702A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023542296A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230069958A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116669763A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021339962A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191538A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002980A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202228695A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053697A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107660205A (zh) * | 2015-04-03 | 2018-02-02 | 因赛特公司 | 作为lsd1抑制剂的杂环化合物 |
| US20180362654A1 (en) * | 2015-12-11 | 2018-12-20 | Regeneron Pharmaceuticals, Inc. | Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade |
| CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| WO2020131627A1 (en) * | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN111420060A (zh) * | 2020-03-30 | 2020-07-17 | 南方医科大学南方医院 | 一种抗肿瘤的联合用药组合物及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO2005110076A2 (en) | 2004-05-10 | 2005-11-24 | Children's Medical Center Corporation | Braf expression in zebrafish and uses thereof |
| AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| KR102373193B1 (ko) * | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| SG11201702381QA (en) | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| KR20250047324A (ko) * | 2017-08-07 | 2025-04-03 | 더 존스 홉킨스 유니버시티 | 암을 평가하고 치료하기 위한 방법 및 재료 |
| US20220175768A1 (en) * | 2019-03-29 | 2022-06-09 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| WO2020208592A1 (en) * | 2019-04-12 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of erdafitinib, its purification and amorphous solid dispersion |
-
2021
- 2021-09-13 US US18/044,232 patent/US20230321087A1/en active Pending
- 2021-09-13 WO PCT/EP2021/075145 patent/WO2022053697A1/en not_active Ceased
- 2021-09-13 AU AU2021339962A patent/AU2021339962A1/en not_active Abandoned
- 2021-09-13 MX MX2023002980A patent/MX2023002980A/es unknown
- 2021-09-13 EP EP21773119.9A patent/EP4210702A1/en active Pending
- 2021-09-13 CN CN202180076145.8A patent/CN116669763A/zh active Pending
- 2021-09-13 JP JP2023516479A patent/JP2023542296A/ja active Pending
- 2021-09-13 CA CA3191538A patent/CA3191538A1/en active Pending
- 2021-09-13 KR KR1020237012158A patent/KR20230069958A/ko not_active Withdrawn
- 2021-09-14 TW TW110134269A patent/TW202228695A/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107660205A (zh) * | 2015-04-03 | 2018-02-02 | 因赛特公司 | 作为lsd1抑制剂的杂环化合物 |
| US20180362654A1 (en) * | 2015-12-11 | 2018-12-20 | Regeneron Pharmaceuticals, Inc. | Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade |
| CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| WO2020131627A1 (en) * | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN111420060A (zh) * | 2020-03-30 | 2020-07-17 | 南方医科大学南方医院 | 一种抗肿瘤的联合用药组合物及其应用 |
Non-Patent Citations (6)
| Title |
|---|
| HAURA ERIC B,等: "Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib", JOURNAL OF THORACIC ONCOLOGY, vol. 15, no. 19, 24 August 2020 (2020-08-24), pages 154 * |
| MARIA TERESA HERRERA-ABREU,等: "Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer", CANCER DISCOVER, vol. 3, no. 9, 1 September 2013 (2013-09-01), pages 1058 - 1071, XP055532713, DOI: 10.1158/2159-8290.CD-12-0569 * |
| MASARU KATOH ,等: "Fibroblast growth factor receptors as treatment targets in clinical oncology", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 16, no. 12, 26 October 2018 (2018-10-26), pages 105 - 122, XP036705943, DOI: 10.1038/s41571-018-0115-y * |
| RUIZ-LLORENTE SERGIO,等: "Mechanisms of resistance to FGFR inhibitors in urothelial cancer cell lines and patients harboring FGFR3 alterations and strategies to overcome it", CANCER RESEARCH, vol. 80, no. 16, 15 August 2020 (2020-08-15), pages 1 - 2 * |
| SASE HITOSHI,等: "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer", MOLECULAR CANCER THERAPEUTICS, vol. 17, no. 10, 1 October 2018 (2018-10-01), pages 2217 - 2225, XP055864622, DOI: 10.1158/1535-7163.MCT-17-1022 * |
| VIPIN YADAV,等: "Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma", J BIOL CHEM, vol. 287, no. 33, 22 June 2012 (2012-06-22), pages 28087 - 28098, XP055141868, DOI: 10.1074/jbc.M112.377218 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542296A (ja) | 2023-10-06 |
| US20230321087A1 (en) | 2023-10-12 |
| WO2022053697A1 (en) | 2022-03-17 |
| KR20230069958A (ko) | 2023-05-19 |
| TW202228695A (zh) | 2022-08-01 |
| MX2023002980A (es) | 2023-06-06 |
| CA3191538A1 (en) | 2022-03-17 |
| EP4210702A1 (en) | 2023-07-19 |
| AU2021339962A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11572405B2 (en) | Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer | |
| TW201819640A (zh) | 癌症之治療性及診斷性方法 | |
| TW201705979A (zh) | 用於具egfr突變陽性之非小細胞肺癌的組合療法 | |
| CN111629729A (zh) | 治疗癌症的方法及组合疗法 | |
| JP2020114849A (ja) | Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用 | |
| JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してegf/egfr経路を抑制する方法および組成物 | |
| CN110636861A (zh) | 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法 | |
| AU2021330539A1 (en) | Treatment of non-small cell lung cancer with egfr mutations | |
| TWI900527B (zh) | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 | |
| CN116568326A (zh) | 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物 | |
| WO2023148702A1 (en) | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies | |
| US20230321087A1 (en) | Fgfr inhibitor combination therapies | |
| WO2024144401A1 (en) | Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs | |
| WO2023138576A1 (zh) | 螺环芳基磷氧化物与抗egfr抗体的药物组合 | |
| CN108367003B (zh) | 乳腺癌脑转移的治疗 | |
| WO2026038160A1 (en) | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies | |
| WO2023138574A1 (zh) | 螺环芳基磷氧化物与抗vegf抗体的药物组合 | |
| HK40081114A (en) | Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma | |
| HK40116078A (en) | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |